Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q3 2020 · 10-Q
Revenue$625.00K$625.00K+54.7% vs Q3 2019 Net Income-$8.75M-$8.75MN/M vs Q3 2019 EPS Diluted-$0.44-$0.44N/M vs Q3 2019 Operating Income-$8,583,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,344,000N/M Margins · derivedOperating margin-1373.3%+527.2 pt vs Q3 2019
Net margin-1400.6%+490.9 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 13, 2020 · 44 d after period end